Home » Business News » 2011 » June » June 16, 2011

Pronova BioPharma hosts Capital Markets Day

June 16, 2011 - London

Lysaker, Norway, 16 June 2011: Pronova BioPharma management will today present the Group's strategic priorities at its Capital Markets Day.

Today's presentations will explore Pronova BioPharma's plans to extend its manufacturing advantages with a target of increasing yields by 50 percent by the end of 2014 compared to 2009 levels.
Together with its partners Abbott, Takeda and Ferrer, Pronova BioPharma also plans to further increase the growth potential of Omacor®, including entering a number of important new markets with the product over the next three years.
Pronova BioPharma will provide an update on its R&D strategy, including pre-clinical results of PRC-4016, a new chemical entity for the treatment of mixed dyslipidemia. The Company has issued a separate press release today with more details on PRC-4016, including plans to initiate clinical trials.
The complete Capital Markets Day presentation can also be found on A webcast will be made available following the event.




Pronova BioPharma is a global leader in research, development and manufacture of lipid therapies derived from nature.


Omacor®, also known as Lovaza(TM) in the US market, and Zodin®, Seacor®, Esapent®, and Eskim® elsewhere, is the first commercialised product developed from Pronova BioPharma's active pharmaceutical ingredient (API).


It is also the first and only EU and U.S. FDA-approved Omega 3-derived prescription drug. Pronova BioPharma estimates that 1.4 million cardiovascular patients, with high elevated levels of triglycerides and/or having suffered a Heart attack, are currently on a prescription for one of the branded products containing its API. 


Marketing and distribution of Pronova BioPharma's key product is currently licensed to both local and global pharmaceutical companies. In 2009, the product reached blockbuster status with sales over USD 1 billion in the current 8 major markets and in 2010 it grew a further 19 percent to USD 1 260 million in 2010, according to IMS Health. It is currently marketed in 56 countries with potential launch in a further 30 countries.


Pronova BioPharma is developing several new, patentable lipid derivatives. The most advanced Lipid Derived Pharmaceutical programme is in the area of dyslipidemia, the abnormal concen­tration of lipids or lipoproteins in the blood.


Pronova BioPharma's headquarters are located at Lysaker in Norway, while production takes place in manufacturing facilities at Sandefjord in Norway and in Kalundborg, Denmark. The company's shares are listed on Oslo Børs with the ticker code PRON.



For further information contact:
Hamed Brodersen, VP Investor Relations and Communications           Tel: +47 40 46 81 10


This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Pronova BioPharma CMD 2011

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Pronova BioPharma ASA via Thomson Reuters ONE



Comment on this story